A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

March 4, 2019

Study Completion Date

March 4, 2019

Conditions
Parkinson's Disease (PD)
Interventions
DRUG

ABBV-951

powder for solution

Trial Locations (12)

32806

Compass Research /ID# 167329, Orlando

40202

University of Louisville /ID# 164997, Louisville

40536

University of Kentucky Chandler Medical Center /ID# 164407, Lexington

44195

Cleveland Clinic Foundation /ID# 164413, Cleveland

63110

Washington University-School of Medicine /ID# 164412, St Louis

66160

Univ Kansas Med Ctr /ID# 166280, Kansas City

85351

Banner Sun Health Res Inst /ID# 165840, Sun City

92354

Loma Linda University /ID# 165592, Loma Linda

92868

Univ CA, Irvine Med Ctr /ID# 165594, Orange

10016-6402

NYU Langone Medical Center /ID# 164924, New York

45267-0585

University of Cincinnati /ID# 165142, Cincinnati

75251-3831

Neurology Consultants of Dallas /ID# 167116, Dallas

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY